SCHEMBL2823356

SCHEMBL2823356

Cc1nc2ccc(F)c(F)c2c(O)c1C

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.36
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
MMP13 P45452 3/20 0.34
PDE10A Q9Y233 4/20 0.33
PDE2A O00408 3/20 0.33
HRH4 Q9H3N8 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
CYP11B2 P19099 1/20 0.31
HTR5A P47898 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
STAT3 P40763 1/20 0.31
ERN1 O75460 1/20 0.31
CASP3 P42574 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28427406 0.87 PARP1 (0.33) PARP1PDE10APDE2APDE3BPDE3A
SCHEMBL2822958 0.83 KDM4E (0.35) PARP1PDE10APDE2APDE3BPDE3A
SCHEMBL2826463 0.80 GCGR (0.35) PARP1TNKSTNKS2MMP13PDE10A
SCHEMBL2823369 0.80 TNKS (0.36) PARP1TNKSTNKS2MMP13KDM4E
SCHEMBL2823352 0.80 PDE2A (0.31) PDE2A
SCHEMBL2820985 0.73 MMP13 (0.34) PARP1TNKSTNKS2MMP13PDE10A
SCHEMBL2820048 0.71 MMP13 (0.37) PARP1TNKSTNKS2MMP13PDE10A
SCHEMBL247885 0.71 HTR5A (0.36) HTR5AKDM4EALDH1A1GAAHPGD
SCHEMBL2823571 0.71 ALDH1A1 (0.33) PDE10APDE2APDE3BPDE3AKDM4E
SCHEMBL2819785 0.71 MMP13 (0.31) PARP1TNKSTNKS2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
CN-1310889-C Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA (JP) 2007-04-18 CN disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
CN-1688193-A Mixed compositions for controlling parasitic insects MEIJI SEIKA KAISHA (JP) 2005-10-26 CN disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
CN-1501918-A Halogen-substituted quinoline derivatives and ectoparasite control agent �����Ƹ���ʽ���� 2004-06-02 CN disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C PARP1 4019/4885TNKS 4821/4885TNKS2 4804/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 PARP1 4813/4885TNKS 4868/4885TNKS2 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.